摘要
目的观察达格列净联合德谷胰岛素利拉鲁肽注射液治疗血糖控制欠佳的糖尿病肾病(diabetic nephropathy,DN)患者的效果。方法选取2022年2月至2024年2月汉中市南郑区人民医院收治的167例血糖控制欠佳的DN患者进行随机对照试验。采用随机数字表法将其分为研究组(83例)和对照组(84例)。研究组男47例,女36例,年龄(57.39±8.16)岁,病程(12.51±2.23)年;DN分期:Ⅱ期48例,Ⅲ期35例。对照组男50例,女34例,年龄(56.47±8.23)岁,病程(12.36±2.19)年;DN分期:Ⅱ期51例,Ⅲ期33例。研究组给予达格列净联合德谷胰岛素利拉鲁肽注射液治疗,对照组给予甘精胰岛素联合达格列净治疗。两组均治疗3个月。比较两组临床疗效、肾功能、血糖、肾脏损伤标志物、外周血细胞因子以及药物不良反应的发生情况。采用t检验、χ^(2)检验进行统计分析。结果治疗前,两组血肌酐(serum creatinine,Scr)、血尿素氮(blood urea nitrogen,BUN)水平和尿白蛋白/肌酐比值(urine albumin-to-creatinine ratio,UACR)比较,差异均无统计学意义(均P>0.05);治疗后,研究组Scr、BUN水平和UACR均低于对照组[(65.24±8.93)μmol/L比(76.12±10.43)μmol/L、(6.23±1.12)mmol/L比(8.04±1.41)mmol/L、(92.32±14.26)mg/g比(106.21±18.35)mg/g],差异均有统计学意义(均P<0.05)。治疗前,两组空腹血糖(fasting blood glucose,FBG)、餐后2 h血糖(2-hour postprandial blood glucose,2hPBG)、糖化血红蛋白(glycosylated hemoglobin,HbA1c)水平比较,差异均无统计学意义(均P>0.05);治疗后,研究组FBG、2hPBG、HbA1c水平均低于对照组[(6.14±0.76)mmoL/L比(7.01±0.89)mmoL/L、(8.16±1.49)mmol/L比(9.32±1.73)mmol/L、(5.21±0.59)%比(5.82±0.68)%],差异均有统计学意义(均P<0.05)。治疗前,两组N-乙酰-β-D-葡萄糖苷酶(N-acetyl-β-D-glucosidase,NAG)、尿视黄醇结合蛋白(retinol-binding protein,RBP)、尿中性粒细胞明胶酶相关脂质运载蛋白(neutrophil gelatinase-associated lipocalin,NGAL)水平比�
Objective To observe the effect of dagliprazin combined with insulin degludec and liraglutide injection in the treatment of patients with diabetic nephropathy(DN)and poor blood glucose control.Methods A total of 167 patients with DN and poor blood glucose control treated at Hanzhong Nanzheng District People's Hospital from February 2022 to February 2024 were selected for the randomized controlled trial,and were divided into a study group(83 cases)and a control group(84 cases)by the random number table method.There were 47 males and 36 females in the study group;they were(57.39±8.16)years old;their disease course was(12.51±2.23)years;there were 48 cases of DN stage Ⅱ and stage 35 cases of stage Ⅲ.There were 50 males and 34 females in the control group;they were(56.47±8.23)years old;their disease course was(12.36±2.19)years;there were 51 cases of DN stage Ⅱ and 33 cases of stage Ⅲ.The study group were treated with dagliprazin and insulin degludec and liraglutide injection,and the control group with dagaglizin and insulin glargine,for 3 months.The clinical efficacies,renal function,blood glucose,markers of renal injury,peripheral blood cytokines,and the incidence rates of adverse drug reactions were compared between the two groups by t and χ^(2) tests.Results Before the treatment,there were no statistical differences in the levels of serum creatinine(Scr)and blood urea nitrogen(BUN)and urine albumin-to-creatinine ratio(UACR)between the two groups(all P>0.05).After the treatment,the levels of Scr and BUN and UACR in the study group were lower than those in the control group[(65.24±8.93)μmol/L vs.(76.12±10.43)μmol/L,(6.23±1.12)mmol/L vs.(8.04±1.41)mmol/L,and(92.32±14.26)mg/g vs.(106.21±18.35)mg/g],with statistical differences(all P<0.05).Before the treatment,there were no statistical differences in the levels of fasting blood glucose(FBG),2-hour postprandial blood glucose(2hPBG),and glycosylated hemoglobin(HbA1c)between the two groups(all P>0.05).After the treatment,the levels of FBG,2hPBG,and HbA
作者
陈颖
段爽莉
李丽
Chen Ying;Duan Shuangli;Li Li(Department of Pharmacy,Hanzhong Nanzheng District People's Hospital,Hanzhong 723100,China;Department of Endocrinology and Nephrology,Pucheng County Hospital,Weinan 715500,China;Department of Pharmacy,Tongchuan Hospital of Traditional Chinese Medicine,Tongchuan 727000,China)
出处
《国际医药卫生导报》
2024年第23期4009-4014,共6页
International Medicine and Health Guidance News
基金
陕西省重点研发计划(2020SF-248)。
关键词
糖尿病肾病
达格列净
德谷胰岛素利拉鲁肽注射液
血糖
疗效
安全性
Diabetic nephropathy
Daglizin
Insulin degludec and liraglutide injection
Blood glucose
Curative effect
Safety
